Ocugen Stock Jumps After Recruiting Jubilant HollisterStier As Manufacturing Partner For COVID-19 Vaccine Candidate

  • Ocugen Inc OCGN has selected Jubilant HollisterStier of Spokane, Washington as its manufacturing partner for COVID-19 vaccine candidate, Covaxin for the U.S. and Canadian markets.
  • "Securing US-based manufacturing capability is a critical step as we prepare to submit our regulatory submissions to the FDA and Health Canada," said J.P. Gabriel, Ocugen's Senior Vice President, Manufacturing and Supply Chain.
  • Covaxin, India's COVID-19 vaccine by Bharat Biotech, is developed in collaboration with the Indian Council of Medical Research.
  • In May, the vaccine demonstrated potential effectiveness against the Brazil variant of SARS-CoV-2, B.1.128.2.
  • Ocugen submitted a "Master File" to the FDA before seeking an emergency use authorization in the U.S.
  • Price Action: OCGN shares are up 7.34% at $6.57 during the market trading session on the last check Tuesday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechNewsHealth CareContractsSmall CapGeneralBriefsCOVID-19 Vaccine
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!